# Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus

> **NCT00093067** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)**

## Conditions studied

- Bacterial Endocarditis
- Bacteremia

## Interventions

- **DRUG:** daptomycin

## Key facts

- **NCT ID:** NCT00093067
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2004-11
- **Final completion:** 2005-02
- **Target enrollment:** — (—)
- **Last updated:** 2017-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093067, "Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00093067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*